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TECHNICAL NOTE
Successful use of double-lumen, silicone rubber catheters for
permanent hemodialysis access
NEIL H. SHUSTERMAN, KATHLEEN KLOSS, and JAMES L. MULLEN
Renal Electrolyte Section, Department of Medicine and Department of Surge,y, University of Pennsylvania School of Medicine, Philadelphia,
Pennsylvania, USA
Repeated, long-term access to the vascular system is a
prerequisite for successful extended care of patients with end-
stage renal disease (ESRD) treated with hemodialysis. Other
modern treatment modalities such as plasmapheresis and pho-
topheresis also require vascular access. Native vessel arterio-
venous fistulae or polytetrafluoroethylene (PTFE) interposition
grafts are the most commonly used forms of permanent vascu-
lar access, but both have their limitations [11. In many older
patients or patients with several prior vascular accesses, pe-
ripheral vessels may be insufficient for the creation of a new
access. Interposition grafts are plagued by venous stenosis,
thrombosis, and infection. In patients with advanced cardiovas-
cular disease, the shunt effect of these grafts may worsen
pre-existing angina or congestive heart failure [2].
Recently, a double-lumen, central venous catheter made of
silicone rubber has been developed for use as a vascular access
device. This device is particularly useful in patients who have
exhausted other vascular access sites or who have severe
cardiovascular disease. In this report, we present our extended
experience with this new access device in hemodialysis pa-
tients.
Methods
We studied all patients who had a double-lumen, silicone
rubber catheter (Permcath, Quinton, Seattle, Washington,
USA) placed for the purpose of hemodialysis during the period
of December, 1984 through November, 1986. A total of 22
catheters were placed in 18 patients during this period. The
Permcath is 36.2 cm long and each lumen has an internal
diameter of 2.03 mm. A Dacron cuff, to anchor the catheter in
the subcutaneous tunnel, is located 19 cm from the distal end of
the catheter. The "arterial" lumen terminates 2.5 cm proximal
to the "venous" lumen in order to reduce recirculation. The
catheters were placed in the operating room by performing a
cutdown over the right external or internal jugular vein and
creating an exit site below the clavicle on the anterior chest
wall. The catheter with its Dacron cuff was pulled through the
subcutaneous tunnel from the exit site and then threaded into
the central venous system under fluoroscopic guidance with the
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tip of the catheter terminating in the right atrium. The external
jugular vein was preferred for ease of insertion if it was
sufficiently large to accept the catheter. After assuring proper
placement, hemostasis, and good blood return, the incision was
closed, the catheter was secured with a suture at the exit site,
and the incision was covered with a gauze bandage and a clear
plastic dressing (Tegaderm, 3M Corp. St. Paul, Minnesota,
USA). Each lumen of the catheter was filled with 7500 units of
heparin sodium (1.5 ml) and capped. The catheter was then
ready for use at any time.
At each dialysis session the catheter was handled in a aseptic
manner. Dialysis nurses wore masks and sterile gloves while
handling the catheter or changing the dressing. At the time the
patient was connected to the extracorporeal circuit, the heparin
was aspirated from each lumen to prevent excessive anticoag-
ulation and to check for patency of the lumen. The connection
was then completed and the dialysis treatment initiated. We
attempted to achieve a blood flow rate of 300 mI/mm for all
treatments. If there was difficulty achieving this flow, then the
arterial and venous limbs of the catheter were reversed ("re-
versed hook-up"). At the end of treatment, each lumen was
flushed with 10 cc of normal saline, filled with 7500 units of
heparin sodium, and capped. Patients were instructed not to
tamper with the catheter or the dressing between treatments.
To analyze catheter performance (blood flow rate, venous
resistance—measured as mean venous pressure, and catheter
hook-up), all of the treatments from December, 1984 through
November, 1986 were reviewed and summarized. Because the
data remained consistent, we ceased collecting this information
after November, 1986. However, to determine the total number
of infectious complications and catheter failures requiring re-
moval, that is, catheter survival, we continued our data collec-
tion through June 30, 1988. Continuous variables are expressed
as the mean SD. To determine catheter survival, life table
analysis was performed [4]. Recirculation was calculated ac-
cording to the standard formula [5].
Results
The patient characteristics are shown in Table 1. The mean
age of the 18 patients (10 female, 8 male) was 53 17 years and
they had been on dialysis 43 51 months (median: 21 months)
at the time of catheter insertion. Fourteen patients had a single
catheter placed and four required a second catheter after the
initial one failed. The double-lumen silicone rubber catheter
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Cause Duration Blood Venous (Total months
Patient of renal of dialysise flow rate resistance treatments of use,
numbera Sex/age failure Months mi/mm mm Hg analyzed) N Final status
I F164 GN 142 271 25 120 32 0 (6) 1 Catheter in use at time
of death
2a F/74 DM 6 259 54 169 45 3 (11) 1 Catheter accidently cut
b 7 263 48 168 62 16 (20) 1 Catheter in use at time
of deatha
3 Ff65 Myeloma 26 286 31 126 27 0 (15) 1 Catheter in use at time
of death
4a Ff51 HTN 4 200 47 123 53 8 (23) 2 Failed—poor flow
b 6 288 26 169 41 3 (38) 3 Failed—poor flow1
5 M/77 HTN 45 292 34 169 34 0 (157) 29 Catheter in use at time
of death
6 M/62 HTN 114 263 64 282 69 2 (30) 2 Catheter in use at time
of death
7 M/41 HTN 63 300 3 141 31 0 (148) 24 Catheter in use at time
of death
8 M/29 Oxalosis 16 288 31 153 56 7 (125) 29 In use
9 M/61 GN 166 300 2 141 31 1(102) 11 In use
10 M/43 HTN 68 297 12 136 42 8 (89) 11 Failed—poor flow5
11 Ff59 HTN 51 297 12 134 21 0(81) 25 In use
l2a Ff39 DM 6 282 29 108 19 2 (20) 2 Failed—infection
b 9 235 69 106 57 5 (7) 1 Failed—infection
13 Ff25 SLE 2 269 24 131 17 0 (29) 2 Failed—infection
14 M/72 HTN 1 255 37 202 32 0 (37) 4 Failed—infection
l5a Ff72 HTN 48 263 51 126 59 24 (98) 7 Failed—poor flow
b 55 297 8 95 20 0 (79) 17 Failed—infection
16 M/38 GN 5 297 11 106 13 0(68) 19 In use
17 Ff29 DM 15 271 32 89 28 4 (34) 8 Failed—infection
IS Ff63 IN 2 264 31 121 32 1(14) 20 In use
a Letters designate more than one catheter placed in the same patient.
b Abbreviationse are: GN, glomerulonephritis; DM, diabetes mellitus; HTN, hypertension; SLE, systemic lupus erythematosis; IN, interstitial
nephritis.
At time of catheter insertion
'1 Treatments where a blood flow rate of 200 mI/mm could not be sustained despite reversal of lines and/or use of urokinase
Catheter was used to return blood during 16 treatments when flow could not be obtained from arterial lumen. Blood flow calculated from four
treatments where arterial lumen was used.
Fibrin sheath during last three treatments resulted in poor flow and discontinuation of catheter.
Catheter required frequent urokinase for successful treatment and was removed.
was chosen as permanent access for one of three reasons: 10
patients (56%) had multiple previously failed accesses with no
other available access sites; four patients (22%) had severe
cardiac disease; and four (22%) patients preferred this access to
avoid repeated venipuncture.
Catheter performance characteristics (Table 1) were studied
during 1,231 treatments (64 55 treatments per catheter [range:
6 to 157]). Blood flow rate was 274 24 mI/mm and the venous
resistance was 141 42 mm Hg. The catheters were connected
in a normal fashion for 1,036 treatments (84%); in a "reversed
hook-up" for 173 (14%) treatments; and in some other fashion
for 22 (2%) treatments. In these last cases some other access
(fistula, femoral catheter, etc.) was used in conjunction with the
double-lumen silicone rubber catheter. Overall, only 84 treat-
ments (7%) were complicated by inadequate blood flow (blood
flow < 200 mi/mm). Recirculation was measured seven times
with the catheter connected in a normal manner and found to be
5.5 1.7%. When the catheter was connected in a "reversed
hook-up" fashion, recirculation was 14 1.7% in three in-
stances.
Local bleeding occurred during the insertion of four (18%)
catheters. This was controlled by local pressure except in one
patient who required red blood cell transfusion and reoperation
to evacuate a hematoma. Eleven suspected or documented
bacteremic episodes occurred during the study for a rate of 1.67
infections per 1000 catheter-days. In five instances, all due to
coagulase-negative staphylococcus, bacteremia was success-
fully eradicated with antibiotic treatment. In the other six
instances (one episode each of Staphylococcus aureus, coagu-
lase-negative staphylococcus, and Kiebsiella pneumoniae, and
three episodes without bacterial growth) it was necessary to
remove the catheter in order to cure the infection. One skin
exit-site infection, due to coagulase-negative staphylococcus,
was successfully treated with antibiotics.
Overall, ten catheters failed and needed to be removed during
the course of the study. Six catheters, as described above, were
removed because of documented or suspected infection that did
not respond to antibiotic therapy. Four catheters with intracta-
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shows that the one-year actuarial catheter survival rate
47% and two-year catheter survival was 41%.
Discussion
We have shown that double-lumen silicone rubber catheters
can be successfully used as vascular access devices in hemodi-
alysis patients for extended periods of time. Previous reports [6,
7] have documented the use of these devices for shorter time
periods with one catheter functioning as long as 324 days [7]. In
our experience, seven of the catheters have been in continuous
use for longer than a year and four catheters have been used for
two years or more. The catheters are well tolerated by the
patients and have the advantages of immediate access to the
vasculature after placement, high blood flow rate, no repetitive
venipuncture, lack of a vascular "steal" syndrome, and no
effect on cardiac function.
It is difficult to compare this catheter to other forms of
vascular access, but one-year patency rates for PTFE grafts
range from 36% [8] to 83% [9]. The reasons for this wide
variability are probably related to patient selection, surgical
skill, and care of the access. Given this variability, we regard
our one-year access survival of 47% as being very acceptable
considering that in most cases the catheter was placed as a
"salvage" procedure in patients who either had no other access
sites or had advanced cardiac disease.
Infection was the most serious complication that occurred in
this series. Our overall infection rate of 1.67 infections per 1000
catheter-days compares favorably with that of catheters placed
at our institution for long-term parenteral nutrition (5 to 7
infections per 1000 catheter-days), although such catheters are
used daily. We did not have any clinically obvious occurrences
of central venous thrombosis as has been occasionally reported
[10], although we did not perform venograms on all our pa-
tients, and no deaths occurred as a direct or indirect complica-
tion of these catheters.
The most annoying difficulty with this access device was
inadequate blood flow which resulted in an inadequate dialysis
treatment 7% of the time. When our nurses encountered poor
was blood flow, they were instructed to reverse the lines so that the
arterial and venous lumens were connected in a reverse fashion.
If reversing the lines did not improve the flow, then there
usually was a fibrin sheath around the tip of the catheter that
acted in a ball-valve manner to restrict flow. In several cases
this was confirmed by a radiographic contrast study [111. The
injection of urokinase into the affected lumen usually corrected
this problem. Urokinase (5,000 to 125,000 units) was adminis-
tered into the occluded catheter lumen as a 1.75 ml bolus. The
lower dose was used initially and, if unsuccessful, successively
larger doses were used until the catheter functioned properly.
The previous dose was usually withdrawn from the lumen
before administering a larger dose or initiating dialysis. No
evidence of systemic fibrinolysis was noted with this technique.
Despite the use of urokinase, four catheters in three patients
had to be removed because of intractable poor flow. We
compared these three patients to the remaining 15 and found
that they did not differ in age, sex distribution, cause of renal
failure, or incidence of left ventricular failure. Blood pressure in
the effected patients was not unusually low (range: 100 to 160/
60 to 90) nor was hematocrit unusually high (range: 16 to 30%).
Interestingly, all four catheters that failed because of poor flow
had been positioned in the superior vena cava while only 44% of
those not removed for poor flow were in such position (P =
0.12, Fisher's exact test). The other catheters were positioned
in the right atrium. Thus we recommend that the tip of these
catheters be placed in the right atrium to provide the best
opportunity for good flow.
We feel that the double-lumen, silicone rubber catheter
represents an advance in long-term vascular access for selected
patients receiving hemodialysis, plasmapheresis, photopheresis
or other modalities involving an extracorporeal blood circuit.
Because the jugular vein route is available in most patients, this
catheter will be increasingly important for those who have
exhausted conventional access sites. As older patients with
vascular disease are being treated with hemodialysis and other
modalities, this access will be appropriate for those patients
who are at risk for exacerbation of cardiac disease or develop-
47%
41%
0 4 8 12 16 20 24 28 32 Fig. 1. Survival of22 double-lumen, silicone
rubber catheters placed in 18 patients for
Time, months after placement long-term hemodialysis.
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ing a vascular "steal" syndrome from a standard access.
Finally, patients who are terrified by repetitive venipuncture
can be successfully treated with this access device. Though our
initial experience has been favorable, further work will be
needed to determine the performance of this device over even
longer periods of time.
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